Scholar Rock Holding Corporation (SRRK)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis.
The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases.
Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
|IPO Date||May 24, 2018|
|CEO||Dr. Jay T. Backstrom M.D., M.P.H.|
301 Binney Street, 3rd Floor
Cambridge, Massachusetts 02142
|Fiscal Year||January - December|
|Edward H. Myles M.B.A., MBA||Chief Financial Officer, Chief Operating Officer and Treasurer|
|Dr. Jay T. Backstrom M.D., M.P.H.||President, Chief Executive Officer and Director|
|Catherine Hu||Vice President of Investor Relations and Corporate Communications|
|Junlin Ho J.D.||General Counsel and Corporate Secretary|
|Caryn Parlavecchio||Chief Human Resources Officer|
|Lisa Amaya Price||Senior Vice President of Human Resources|
|Dr. George G. Nomikos M.D., Ph.D.||Senior Vice President of Medical and Clinical Sciences and Head of Muscle Therapeutic Area|
|Erin Moore||Senior Vice President of Finance|
|Ryan Iarrobino||Senior Vice President of Clinical Development and Operations|
|Dr. Jing L. Marantz M.B.A., M.D., Ph.D.||Chief Medical Officer|
Latest SEC Filings
|May 9, 2023||10-Q||Quarterly Report|
|May 9, 2023||8-K||Current Report|
|May 1, 2023||ARS||Filing|
|May 1, 2023||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|May 1, 2023||DEF 14A||Other definitive proxy statements|
|Apr 10, 2023||8-K||Current Report|
|Mar 13, 2023||8-K||Current Report|
|Mar 7, 2023||8-K||Current Report|
|Mar 7, 2023||S-8||Securities to be offered to employees in employee benefit plans|
|Mar 7, 2023||10-K||Annual Report|